Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. He represents buyers, sellers and investment banks in his M&A practice, as well as the private equity and venture sources investing in such companies and investment banks serving such industries.
During his distinguished career, Mr. Cable has played a central role in executing more than 400 M&A transactions, with a particular focus on the technology and life sciences industries. In addition to his M&A work, Mr. Cable regularly represents issuers and underwriters in a myriad of capital market offerings.
Mr. Cable’s representative clients include, among others: AMAG, Ansys, AvroBio, Aura, Cerevel, Citrix, Corbus, Flagship Pioneering, Mirati, Moderna, MyoKardia, Ohana, PAREXEL, PTC, Repertoire Immune Medicines, Plug Power, Rubius, Shields Healthcare Solutions, Spark, Valo Health, and Yumanity.
Representative Transactions
His recent and notable representations include:
- MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
- AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
- Macquarie Capital and GCM Grosvenor in connection with their 2020 agreement to acquire Alaska Communications Systems Group ($500 million)
- Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp II ($440 million)
- Financial advisor in connection with Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
- Moderna in its 2020 follow-on public offerings ($500 million in March and $1.34 billion in May)
- The Transaction Committee of Sprint in connection with Sprint Corporation’s 2020 merger with T-Mobile US, Inc. ($26 billion)
- Financial advisor in connection with Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
- Financial advisor in connection with Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
- Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
- Financial advisor in connection with Arqule’s 2020 acquisition by Merck ($2.7 billion)
- Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
- Moderna in its 2018 record initial public offering ($604 million)
- Keryx in its 2018 merger with Akebia ($1.3 billion)
- Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
- The private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals
- The abandoned 2018 acquisition of NXP by Qualcomm ($47 billion)
- inviCRO in its 2017 sale to Konica Minolta (Japan) ($300 million)
- PAREXEL in its 2017 sale to Pamplona ($5 billion)
- AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
- Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
- Financial advisor in connection with Pharmacyclics’ 2015 sale to AbbVie ($21 billion)
- AMRI in its 2016 and 2015 cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain)
- The private company sale of Stemcentrix to Abbvie ($5.8 billion)
- The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion)
- Xoom in its 2015 sale to PayPal ($1 billion)
- Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
- Eloqua in its 2012 sale to Oracle ($1 billion)
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including most recently the representation of the Transaction Committee of Sprint in Sprint Corporation’s merger with T-Mobile US, Inc.
